226 related articles for article (PubMed ID: 33623142)
21. Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
Adamo A; Chin P; Keane P; Assi SA; Potluri S; Kellaway SG; Coleman D; Ames L; Ptasinska A; Delwel HR; Cockerill PN; Bonifer C
Leukemia; 2023 Jan; 37(1):102-112. PubMed ID: 36333583
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.
Quintana-Bustamante O; Lan-Lan Smith S; Griessinger E; Reyal Y; Vargaftig J; Lister TA; Fitzgibbon J; Bonnet D
Leukemia; 2012 Jul; 26(7):1537-46. PubMed ID: 22371011
[TBL] [Abstract][Full Text] [Related]
23. CEBPA-regulated lncRNAs, new players in the study of acute myeloid leukemia.
Hughes JM; Salvatori B; Giorgi FM; Bozzoni I; Fatica A
J Hematol Oncol; 2014 Sep; 7():69. PubMed ID: 25252716
[TBL] [Abstract][Full Text] [Related]
24. C/EBPα in normal and malignant myelopoiesis.
Friedman AD
Int J Hematol; 2015 Apr; 101(4):330-41. PubMed ID: 25753223
[TBL] [Abstract][Full Text] [Related]
25. Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation.
Avellino R; Delwel R
Blood; 2017 Apr; 129(15):2083-2091. PubMed ID: 28179278
[TBL] [Abstract][Full Text] [Related]
26. Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin.
Han Y; Ye A; Zhang Y; Cai Z; Wang W; Sun L; Jiang S; Wu J; Yu K; Zhang S
PLoS One; 2015; 10(8):e0136484. PubMed ID: 26308531
[TBL] [Abstract][Full Text] [Related]
27. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
Pabst T; Mueller BU
Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
[TBL] [Abstract][Full Text] [Related]
28. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
[TBL] [Abstract][Full Text] [Related]
29. Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation.
Rishi L; Hannon M; Salomè M; Hasemann M; Frank AK; Campos J; Timoney J; O'Connor C; Cahill MR; Porse B; Keeshan K
Blood; 2014 Apr; 123(15):2389-400. PubMed ID: 24516045
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
31. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
Cooper S; Guo H; Friedman AD
PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
[TBL] [Abstract][Full Text] [Related]
32. Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.
Zhang H; Alberich-Jorda M; Amabile G; Yang H; Staber PB; Di Ruscio A; Welner RS; Ebralidze A; Zhang J; Levantini E; Lefebvre V; Valk PJ; Delwel R; Hoogenkamp M; Nerlov C; Cammenga J; Saez B; Scadden DT; Bonifer C; Ye M; Tenen DG
Cancer Cell; 2013 Nov; 24(5):575-88. PubMed ID: 24183681
[TBL] [Abstract][Full Text] [Related]
33. C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.
Alberich-Jordà M; Wouters B; Balastik M; Shapiro-Koss C; Zhang H; Di Ruscio A; Radomska HS; Ebralidze AK; Amabile G; Ye M; Zhang J; Lowers I; Avellino R; Melnick A; Figueroa ME; Valk PJ; Delwel R; Tenen DG
J Clin Invest; 2012 Dec; 122(12):4490-504. PubMed ID: 23160200
[TBL] [Abstract][Full Text] [Related]
34. C/EBPα dysregulation in AML and ALL.
Paz-Priel I; Friedman A
Crit Rev Oncog; 2011; 16(1-2):93-102. PubMed ID: 22150310
[TBL] [Abstract][Full Text] [Related]
35. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
Kato N; Kitaura J; Doki N; Komeno Y; Watanabe-Okochi N; Togami K; Nakahara F; Oki T; Enomoto Y; Fukuchi Y; Nakajima H; Harada Y; Harada H; Kitamura T
Blood; 2011 Jan; 117(1):221-33. PubMed ID: 20884804
[TBL] [Abstract][Full Text] [Related]
36. CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation.
Federzoni EA; Humbert M; Torbett BE; Behre G; Fey MF; Tschan MP
Sci Rep; 2014 Mar; 4():4261. PubMed ID: 24584857
[TBL] [Abstract][Full Text] [Related]
37. Disruption of the C/EBPα-miR-182 balance impairs granulocytic differentiation.
Wurm AA; Zjablovskaja P; Kardosova M; Gerloff D; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Benoukraf T; Fricke S; Hilger N; Müller AM; Bill M; Schwind S; Tenen DG; Niederwieser D; Alberich-Jorda M; Behre G
Nat Commun; 2017 Jun; 8(1):46. PubMed ID: 28663557
[TBL] [Abstract][Full Text] [Related]
38. Investigation of C/EBPalpha function in human (versus murine) myelopoiesis provides novel insight into the impact of CEBPA mutations in acute myelogenous leukemia (AML).
Niebuhr B; Iwanski GB; Schwieger M; Roscher S; Stocking C; Cammenga J
Leukemia; 2009 May; 23(5):978-83. PubMed ID: 19020539
[No Abstract] [Full Text] [Related]
39. HoxA9 binds and represses the Cebpa +8 kb enhancer.
Peng L; Guo H; Ma P; Sun Y; Dennison L; Aplan PD; Hess JL; Friedman AD
PLoS One; 2019; 14(5):e0217604. PubMed ID: 31120998
[TBL] [Abstract][Full Text] [Related]
40. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
